Opentrons is establishing itself as a leader in flexible lab automation with thousands of robots in labs worldwide, creating ongoing sales opportunities through recurring consumables, software upgrades, and service contracts. The company operates two business units: Opentrons Robotics, which provides flexible liquid handling lab robots used by thousands of institutions, and Neochromosome, which offers genome-scale cell engineering solutions for biopharma and biotech. Recent product launches like Flex Prep and Opentrons for Education showcase the company's focus on accessible, no-code robotic platforms for academic and research institutions.
Cyborg Score Rationale
Opentrons holds market leadership in entry-level lab automation with global deployment across 40+ countries and an expanding installed base driving recurring revenue. The company has secured over $20M in funding and operates multiple revenue streams through consumables and software. However, as a private company, visibility on recent profitability and cash flow remains limited.
Top Insights
Opentrons has recent financing of over $20 million and annual revenues estimated between $50 million and $100 million, positioning the company for further expansion. This revenue scale enables sustained R&D investment and global market penetration.
Recent product launches including Flex Prep and Opentrons for Education signal market expansion into education and adjacent verticals, diversifying revenue beyond core research and diagnostic customers and reducing single-customer concentration risk.
Opentrons significantly bolstered its executive leadership in early to mid-2023 with key appointments including a new Chief Financial Officer (January 2023), Chief People Officer (March 2023), and Chief Commercial Officer (April 2023) to steer the company through its next growth phase.
Named Competitors
Tecan Freedom EVO — Enterprise lab automation and liquid handling robotics
Hamilton MICROLAB — Automated liquid handling workstations